Gilead's Livdelzi Hits Primary Endpoint in Phase 3 PBC Trial with Strong Safety
GILD sits 25% above its 52-week low of $104.46.
Summary
Gilead's Livdelzi (seladelpar) achieved statistically significant composite ALP normalization in its Phase 3 IDEAL trial for Primary Biliary Cholangitis (PBC). The drug also demonstrated a generally well-tolerated safety profile with no new concerns. This positive clinical data is a crucial step towards regulatory approval and commercialization, potentially adding a new revenue stream for Gilead. It also validates the company's ongoing investment in its pipeline, following recent strategic acquisitions.
At the time of this announcement, GILD was trading at $130.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.8B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.